Physician profile
William Liggett
NPI 1336230424
$970.64
in general payments reported to CMS, 2019-2025
15 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $46.97 · 2022: $79.11 · 2023: $181 · 2024: $138 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $370.72 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $78.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $67.16 | 2023-2025 | Lynparza |
| Celgene Corporation | $65.97 | 2019-2024 | Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $64.79 | 2019-2023 | Opdivo |
| Biocompatibles, INC. | $60.15 | 2019 | |
| Daiichi Sankyo INC. | $38.41 | 2022-2024 | Enhertu |
| Array Biopharma INC | $36.95 | 2024 | Mektovi, Lorbrena, Braftovi |
| Novartis Pharmaceuticals Corporation | $36.85 | 2023-2025 | |
| Astellas Pharma US INC | $34.29 | 2019-2023 | Xospata |
| Regeneron Healthcare Solutions, INC. | $28.84 | 2024 | Libtayo |
| Novocure INC. | $28.49 | 2022 | |
| Apellis Pharmaceuticals, INC. | $23.88 | 2023 | Empaveli |
| Amgen INC. | $22.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Liggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.